海泰科(301022.SZ):目前公司汽車注塑模具已應用於包括比亞迪等新能源車型
格隆匯11月9日丨有投資者網上向海泰科(301022.SZ)提問,“奇瑞智界s7新車型上市,公司是否有提供模具,輕車量化提供的花,一套大致多少錢一套”
公司回覆表示,目前,公司汽車注塑模具已應用於包括平治、寶馬、大眾、奧迪、通用、比亞迪、吉利、理想、小鵬、前途、蔚來、Rivian、高合、比亞迪、問界、小米、奇瑞等新能源車型。公司根據營銷策略、銷售成本、市場狀況、技術和製造複雜程度制定定價策略,具體到每套模具,價格不等。基於商業保密原則,關於價格等業務信息不便透露,敬請理解。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.